- Molecular NameErlotinib
- Synonymerlotinib; OSI-774
- Weight393.443
- Drugbank_IDDB00530
- ACS_NO183321-74-6
- Show 3D model
- LogP (experiment)3.126
- LogP (predicted, AB/LogP v2.0)3.24
- pka5.42
- LogD (pH=7, predicted)3.21
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.4
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors1
- No.of HBond Acceptors7
- No.of Rotatable Bonds11
- TPSA74.73
- StatusFDA approved
- AdministrationN/A
- PharmacologyA drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is a tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).
- Absorption_value60.0
- Absorption (description)Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding93.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIn vitro assays of cytochrome P450 metabolism showed that erlotinib is metabolized primarily by CYP3A4 and to a lesser extent by CYP1A2, and the extrahepatic isoform CYP1A1.
- Half life36.2 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include diarrhea, rash, and liver transaminase elevation.
- LD50 (rat)N/A
- LD50 (mouse)N/A